Teva wins US FDA approval for Xgeva biosimilar DEGEVMA
FDA clearance covers DEGEVMA (denosumab-adet) as a biosimilar to Amgen's Xgeva. Teva said U.S. launches for DEGEVMA and PONLIMSI are expected in coming months.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.